ALNA News and Press, Allena Pharmaceuticals Inc. From 07/13/21

Allena Pharmaceuticals (ALNA) inks agreements with several institutional and accredited investors for the purchase and sale of 21,357,744 common shares and warrants to purchase up to 10,678,872 common stock, at $1.311/share and warrant, in a registered direct offering priced at-the-market.Exp...

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...

Allena Pharmaceuticals ([[ALNA]]) provides progress updates on its clinical programs: ALLN-346 in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease ((CKD)) and reloxaliase (ALLN-177) in development for the treatment of patients with...

-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021- -Reloxaliase advancing in URIROX-2 Pivotal Phase 3 study; revised interim analysis now targeted for Q1 2022- NEWTON, Mass., July...

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and ki...

NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...

Penny Stocks Are Popular Right Now, Here Are 5 to Watch If your goal is to make quick returns in the stock market, penny stocks may be the right investment for you. While long-term investing with penny stocks is possible, short-term or swing trading is much more common. Nevertheless...

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expected 3Q 2021 -- -- On-track to initiate Phase 2a program for ALLN-346 in 3Q 2...

Allena Pharmaceuticals Inc. (NASDAQ:ALNA) traded at a new 52-week low today of $1.06. Approximately 4.3 million shares have changed hands today, as compared to an average 30-day volume of 812,000 shares. Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engage...

NEWTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney d...